Literature DB >> 23189228

Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study.

Seyed Moayed Alavian1, Seyed Vahid Tabatabaei, Teyyeb Ghadimi, Farzam Beedrapour, Sedigheh Amini Kafi-Abad, Ahmad Gharehbaghian, Hassan Abolghasemi.   

Abstract

INTRODUCTION: Hepatitis B virus (HBV) infection is a serious global public health problem affecting billions of people globally. The lack of information of its seroprevalence among the general population is an obstacle for formulating effective policies to reduce the burden viral hepatitis. Therefore, this population based serological survey was conducted in Kurdistan province, where no epidemiological data was available to determine the prevalence and risk factors of HBV infection.
METHODS: 1613 healthy subjects were selected from all districts of Kurdistan province (in the western of Iran) using random cluster sampling. The subjects' age ranged from 6 to 65 years old. Serum samples were tested for HBcAb, HBsAg and anti-HDV antibody. Screening tests were carried out by the third generation of ELISA. Various risk factors were recorded and multivariate analysis was performed.
RESULTS: The prevalence of HBsAg and HBcAb in Kurdistan was before 0.80% (95% CI 0.44; 1.34) and 5.02% (95% CI 4.03; 6.17), respectively. None of HBsAg carriers had positive anti-HDV antibody. Predictors of HBsAg or HBcAb in multivariate analysis were: older age and marriage. We did not find any significant differences between males and females.
CONCLUSION: Our population based study suggests that intrafamilial HBV transmission plays a major role in HBV transmission in Kurdistan province. Furthermore, approximately 5% of general population in this province has prior exposure to HBV and less than 1% is HBsAg carriers. However, we could not find any case of HDV infection among them.

Entities:  

Keywords:  Hepatitis B virus; Iran; epidemiology; prevalence

Year:  2012        PMID: 23189228      PMCID: PMC3506088     

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


INTRODUCTION

Hepatitis B is one of the major health problems in the world and around two billion people are infected globally and most of them are Asian.[1] Just like other developing countries, hepatitis B virus (HBV) infection is the main cause of chronic liver disease in Iran.[23] It has been reported that 51-56% of Iranian cirrhotic patients are hepatitis B surface antigen (HBsAg) positive.[45] In 1979 seroprevalence of HBsAg was reported between 2.5% and 7.2%.[6] In that time it was estimated that approximately one million HBsAg positive carriers were living among 35 million Iranians. In 1990s rate of HBV infection was reported between 1.07 and 5% among blood donors or general population[37-10] and in 2000s between 1 and 2% in different provinces.[10-14] In fact, during the last two decades, obligatory infantile HBV vaccination with more than 95% of coverage has led to significant decline in rate of HBV infection in Iran.[21516] In 2008, in a systematic review of literature we gathered and pooled available data on seroepidemiology of HBV infection in general population of Iran. The HBV infection prevalence in Iran was estimated 2.14% (95% CI: 1.92; 2.35). Despite unreliable meta-analysis, its comprehensive literature review showed that, the data were available for only 7 out of 30 provinces of Iran.[17] Kurdistan is one of the provinces with missing data regarding seroprevalence of HBV infection. From public health view, in addition to seroepidemiology, the risk factors of HBV infection is of great important, since with proper intervention, HBV seroepidemiology can be contained. The major known risk factors for transmission of HBV are from HBsAg positive pregnancy, transfusion, hospitalization, tattoo, intravenous drug abuse and high risk sexual behaviors.[1819] Since the lack of information on HBV prevalence and distribution of its risk factors among the general population is an obstacle for formulating effective policies to reduce the burden viral hepatitis, this population based study was designed to determinate accurate estimate of HBV infection epidemiology and associated risk factors in Kurdistan province. Kurdistan is a province with 54,592 km2 area and 2,880,312 populations that is located at western part of Iran. This province is of great importance since it has common border with Iraq that have impaired health care system and lacks major health statistics including rate HBV infection.

METHODS

Study population

The general population of Kurdistan (in the western of Iran) was studied [Table 1]. Subjects between 6 and 65 years of age were included. Temporal inhabitants of the household, non-Iranian nationalities or those who did not consent to the study were excluded. The demographic characteristics of Kurdistan province are given in Table 2.
Table 1

Census information–Kurdistan and 9 studied districts

Table 2

Demographic data of the study population

Census information–Kurdistan and 9 studied districts Demographic data of the study population

Sample size calculation

The sample size was determined using [DEFF*Np(1-p)]/[(d2/Z21-α/2*(N-1)+p*(1-p)] equation, when N is population size (1,440,518), P is Hypothesized % frequency of outcome factor in the population (here 5% ± 2), d is Confidence limits as % of 100 (absolute ±%, here 2%) and DEFF is design effect for cluster surveys that was set to 1. The sample size was calculated 1796 subjects with 99.99% confidence level. This number was rounded up to 2000 subjects.

Sampling and randomization

Clustered random sampling was used. One hundred clusters were selected from nine districts within Kurdistan province with a cluster size of 20. Postal code or family registry code was used to randomly select the first household for each cluster. Blood samples were obtained from each subject and a questionnaire was completed by a trained interviewer. The questionnaire included demographic and anthropometric data and risk factors for hepatitis B.

Laboratory tests

The blood samples were transferred to the regional laboratory. After separation of serum from blood samples in local laboratory, serums were frozen in –20°C and transferred to the central laboratory of Iranian Blood transfusion organization. HBsAg, HBcAb, and anti-HDV antibody were evaluated using Enzygnost HBsAg, 5.0 kit (Dade Behring, Germany), Hepanostica anti-HBc Uni-Form kit (Biomerieux, France), and (ETI-ABDELTAK-2; Diasorin, Dietzenbach, Germany), respectively.

Ethics

The study was approved by the Institutional Review Board of the Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver Disease and Iranian Blood Transfusion Organization. Written informed consent was obtained from all subjects before data collection.

Statistical analysis

Statistics of all variables are summarized in Tables. Continuous variables are presented as mean values±standard deviation (SD), while qualitative and discrete variables are presented as absolute and relative frequencies in the form of percentage. Chi-squared test was applied to assess associations between categorical variables. The 95% CI for rate of HBcAb or HBsAg positivity was calculated by Mid P-Exact method if NPQ ≤5 when N is sample size, P is the rate of positive cases and Q is 1 – (rate of positive cases). If NPQ had been ≥5, then normal approximation method (Wald) would have been used to make 95% CI. The comparisons between continuous and qualitative variables were performed by student's t-test. Multivariable logistic-regression analysis involving recorded risk factors and patients’ characteristics that had significant P value in univariate analysis of HBV serostatus was performed to identify independent predictors of positive HBV seromarkers. A stepwise procedure was deployed with P = 0.05 as the threshold level for variables to be entered into and retained in the final model, and P = 0.1 as the threshold level for variables to be removed. All computations were carried out using SPSS version 18.

RESULTS

A total of 2000 subjects were interviewed from 9 districts of Kurdistan province. 387 subjects that refused to give blood sample or had inadequate sample were excluded. A total of 1613 samples were analyzed. The demographic characteristics of study population are given in Table 2. Totally 81, 5.02% (95% CI 4.03; 6.17), and 13, 0.80% (95% CI 0.44; 1.34) subjects from 1613 participants were HBcAb and HBsAg positive, respectively. The rate of positive HBV seromarkers in various districts of Kermanshah province is given in Figure 1.
Figure 1

Geographical distribution of HBcAb and HBsAg seropositivity in various districts of Kurdistan province

Geographical distribution of HBcAb and HBsAg seropositivity in various districts of Kurdistan province HBcAb seroprevalence ranged between 2 and 7%. No case of HBsAg positive was found in Divandare, Bijar, Kamyaran and Marivan. In Sarv Abad, Ghorveh and Baneh, around 2% of general population was HBsAg positive. In univariate analysis, there was no significant difference in the rate of HBsAg (P=0.1) or HBcAb (P=0.8) among various districts. Table 3 shows the age-specific seroprevalence of HBcAb for each sex. It can be seen that HBcAb seroprevalence and the difference between males and females increase with age group.
Table 3

Seroprevalence of HBcAb in male and female subjects in different age groups

Seroprevalence of HBcAb in male and female subjects in different age groups Figure 2 shows univariate analyses of studied risk factors. Marital status, age and literacy were significant risk factors of HBcAb or HBsAg seropositivity.
Figure 2

Risk factors associated with HBcAb or HBsAg in univariate analysis

Risk factors associated with HBcAb or HBsAg in univariate analysis Figure 3 shows multivariate analysis of risk factors with significant P values in univariate analyses. Age group 46-65 and marital status were independent predictors of HBcAb or HBsAg seropositivity.
Figure 3

Risk factors associated with HBcAb or HBsAg in multivariate analysis

Risk factors associated with HBcAb or HBsAg in multivariate analysis

DISCUSSION

Hepatitis B virus (HBV) infection is a major cause of liver disease in the world. WHO has estimated that in more than 350 million people acute infection have turned to chronic infection. It is also estimated that more than 500,000 deaths occur annually mainly of cirrhosis and hepatocellular carcinoma caused by chronic HBV infection.[26] Monitoring of several scattered population based studies that have been carried out in different part of Iran shows that HBV prevalence has decreased dramatically in Iranian population during the last decade. It is now considerably less than many developing countries and only slightly higher than that seen in industrialized countries such as the United States.[2021] Improvement of the people's knowledge about HBV risk factors, national vaccination program from 1993 for all neonates, vaccination of high risk groups such as healthcare workers and the introduction of disposable syringes for use in vaccinations, hospitals and clinics might justify this decrease. Unfortunately there were no available data from Kurdistan province so we could identify the trend of HBV epidemiology in the general population after introduction of universal HBV vaccination program. Our current survey shows that approximately less than 1% and around 5% of the general population in Kurdistan province are chronic HBsAg carrier and had previous exposure to HBV infection. We can estimate that 23,042 chronic HBsAg carriers are living in this province and 144,016 have resolved HBV infection and some have occult HBV infection and are at greater risk of cirrhosis and hepatocellular carcinoma. In multivariate analysis only age and marital status were independent risk factors for HBV seropositivity. Age is a common risk factor that almost is reported in all of seroepidemiologic studies of HBV infection. The reason is that the risk and cumulative frequency of high risk behaviors increase with age and consequently increase the rate of HBV exposure. Another independent risk factor of HBV seropositivity was being married. 10 and 1% of married subjects had positive HBcAb and HBsAg, respectively. Therefore checking couples before marriage and vaccination are advisable since they can considerably decrease the prevalence of HBV infection in this province.

CONCLUSION

Our population based study suggests that intrafamilial HBV transmission plays a major role in HBV transmission in Kurdistan province. Furthermore, approximately 5% of general population in this province has prior exposure to HBV and less than 1% is HBsAg carriers. However, we could not find any case of HDV infection among them.
  11 in total

1.  Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran.

Authors:  A H M Alizadeh; M Ranjbar; S Ansari; A MirArab; S M Alavian; K Mohammad; P Adibi; Gh H Sadri; F Keramat; A Ardalan; M Arabi; S Gharekhani; A Ataei; Gh R Amraei; M Hosseinzadeh; S Hatami; M Zali
Journal:  East Mediterr Health J       Date:  2006-09       Impact factor: 1.628

2.  Epidemiology of viral hepatitis among Iranian population--a viral marker study.

Authors:  H Farzadegan; M Shamszad; K Noori-Arya
Journal:  Ann Acad Med Singapore       Date:  1980-04       Impact factor: 2.473

3.  Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey.

Authors:  George N Ioannou
Journal:  Ann Intern Med       Date:  2011-03-01       Impact factor: 25.391

4.  Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone.

Authors:  Ali Kabir; Seyed-Moayed Alavian; Navid Ahanchi; Reza Malekzadeh
Journal:  Hepatol Res       Date:  2006-09-11       Impact factor: 4.288

5.  Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers.

Authors:  Peyman Adibi; Rezvan Ghassemian; Seyed-Moayed Alavian; Mitra Ranjbar; Amir H Mohammadalizadeh; Fariborz Nematizadeh; Mojgan Mamani; Mahdi Rezazadeh; Fariba Keramat; Ali Ardalan; Abbas Esmaeili; Mohammad R Zali
Journal:  Saudi Med J       Date:  2004-10       Impact factor: 1.484

Review 6.  Epidemiology of hepatitis B and C viruses: a global overview.

Authors:  Helen S Te; Donald M Jensen
Journal:  Clin Liver Dis       Date:  2010-02       Impact factor: 6.126

7.  Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study.

Authors:  S Amini; M F Mahmoodi; S Andalibi; A A Solati
Journal:  J Trop Med Hyg       Date:  1993-10

Review 8.  The epidemiology of viral hepatitis in the United States.

Authors:  M J Alter; E E Mast
Journal:  Gastroenterol Clin North Am       Date:  1994-09       Impact factor: 3.806

9.  Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran.

Authors:  A A Ghavanini; M R Sabri
Journal:  East Mediterr Health J       Date:  2000 Sep-Nov       Impact factor: 1.628

10.  Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users.

Authors:  Mohammad Mehdi Mir-Nasseri; Ashraf Mohammadkhani; Hamid Tavakkoli; Esmaeil Ansari; Hossein Poustchi
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

View more
  23 in total

1.  Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination.

Authors:  Zohreh Borzooy; Seyed Mohammad Jazayeri; Abbass Mirshafiey; Azam Khamseh; Masoud Karkhaneh Mahmoudie; Pedram Azimzadeh; Babak Geravand; Mohammad Ali Boroumand; Mina Afshar; Vahdat Poortahmasebi; Mostafa Hosseini; Adrian Streinu-Cercel
Journal:  Germs       Date:  2015-12-02

2.  Protection Provided by Hepatitis B Vaccine in Adult Population of Chaharmahal and Bakhtiari Province, Iran in 2013.

Authors:  Masoumeh Moezzi; Reza Imani
Journal:  J Clin Diagn Res       Date:  2016-04-01

3.  Global risk assessment of aflatoxins in maize and peanuts: are regulatory standards adequately protective?

Authors:  Felicia Wu; Shaina L Stacy; Thomas W Kensler
Journal:  Toxicol Sci       Date:  2013-06-12       Impact factor: 4.849

Review 4.  Prevention and Management of Chronic Hepatitis B.

Authors:  Mamatha Bhat; Peter Ghali; Marc Deschenes; Philip Wong
Journal:  Int J Prev Med       Date:  2014-12

5.  The assessment of hepatitis B seroprevalence in persons with intravenous drug use history in the Isfahan province: Community-based study.

Authors:  Mahsa Khodadoostan; Behrooz Ataei; Ahmad Shavakhi; Tahmine Tavakoli; Zary Nokhodian; Majid Yaran
Journal:  J Res Med Sci       Date:  2014-01       Impact factor: 1.852

6.  A population based study on hepatitis B virus in northern iran, amol.

Authors:  Hossein Keyvani; Masoudreza Sohrabi; Farhad Zamani; Hossein Poustchi; Hossein Ashrafi; Fatemeh Saeedian; Mansooreh Mooadi; Nima Motamed; Hossein Ajdarkosh; Mahmoodreza Khonsari; Gholamreza Hemmasi; Mitra Ameli; Ali Kabir; Mahmoud Khodadost
Journal:  Hepat Mon       Date:  2014-08-17       Impact factor: 0.660

7.  Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis.

Authors:  Li-Hui Long; Cai-Qin Xue; Jun-Feng Shi; Juan-Ni Dong; Li Wang
Journal:  Hepat Mon       Date:  2015-07-22       Impact factor: 0.660

8.  Hepatitis B seroprevalence and risk factors in adult population of chaharmahal and bakhtiari province in 2013.

Authors:  Masoumeh Moezzi; Reza Imani; Nasser Khosravi; Behrouz Pourheidar; Forouzan Ganji; Ali Karimi
Journal:  Hepat Mon       Date:  2014-05-03       Impact factor: 0.660

Review 9.  Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis.

Authors:  Mostafa Salehi-Vaziri; Farzin Sadeghi; Amir Almasi Hashiani; Mohammad Gholami Fesharaki; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-04-26       Impact factor: 0.660

10.  Seroprevalence and Knowledge of Hepatitis B Virus Infection Among LaboratoryWorkers at Kilimanjaro Christian Medical Centre in Moshi, Tanzania.

Authors:  Richard E Machange; Dominic Mosha; Jeremia J Pyuza; Balthazar B Nyombi; Elichilia R Shao
Journal:  East Afr Health Res J       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.